Evaluation of rapid tests for diagnosis of acute hepatitis E

Paola Chionne; Elisabetta Madonna; Giulio Pisani; Stefania Taffon; Giuseppina La Rosa; Angela Candido; Stefano Dettori; Elena Tritarelli; Michele Equestre; Roberto Bruni; Anna Rita Ciccaglione

doi:10.1016/j.jcv.2016.02.005

Evaluation of rapid tests for diagnosis of acute hepatitis E

J Clin Virol. 2016 May:78:4-8. doi: 10.1016/j.jcv.2016.02.005. Epub 2016 Feb 11.

Affiliations

¹ Department of Infectious, Parasitic and Immune-Mediated Diseases, Istituto Superiore di Sanità, Rome, Italy.
² Center for Immunobiologicals Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
³ Department of Infectious, Parasitic and Immune-Mediated Diseases, Istituto Superiore di Sanità, Rome, Italy. Electronic address: stefania.taffon@iss.it.
⁴ Department of Environment and Primary Prevention, Istituto Superiore di Sanità, Rome, Italy.
⁵ Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy.

PMID: 26930580
DOI: 10.1016/j.jcv.2016.02.005

Abstract

Background: Hepatitis E virus diagnosis still presents difficulties due to discordant results among diagnostic tests.

Objectives: The aim of this study was to evaluate the performance of two rapid tests for detection of anti-HEV IgM antibodies.

Study design: The rapid tests were compared with three commercial anti-HEV ELISA assays and one Real-Time PCR assay on 59 sera from patients with acute viral non-AC hepatitis.

Results: The presence of anti-HEV IgM antibodies was evaluated by two rapid tests (Wantai and Assure) on 25 HEV RNA positive samples. Anti-HEV IgM antibodies were detected in 24/25 and 23/25 samples respectively. The sensitivity and specificity of Wantai and Assure Rapid tests were evaluated using the 25 HEV RNA positive samples and 50 HEV RNA negative samples (including sera from acute-phase HAV and HBV infections and blood donors). Overall, the sensitivity of Wantai Rapid and Assure Rapid tests was 96.1% and 92.6% respectively; the specificity of the 2 tests was 100%.

Conclusion: Our data suggest the potential use of anti-HEV IgM rapid assays as a first line test in primary health care settings, particularly useful for patients with chronic liver disease or pregnant women who urgently need an antiviral treatment.

Keywords: ELISA assays; Hepatitis E; Rapid tests; Real-Time PCR.

Publication types

Comparative Study
Evaluation Study
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Viral / blood*
Chromatography, Affinity / methods*
Hepatitis E / diagnosis*
Hepatitis E virus / immunology*
Humans
Immunoglobulin M / blood*
Sensitivity and Specificity

Substances

Antibodies, Viral
Immunoglobulin M